A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study

ConclusionDRAGON study demonstrated the efficacy and safety of erenumab 70  mg in patients with CM from Asia. No new safety signals were observed during the DBTP compared with the previous trials.Trial registrationNCT03867201
Source: The Journal of Headache and Pain - Category: Neurology Source Type: research